Urethral Neoplasia

Urethral neoplasia refers to primary or secondary tumors arising from the epithelial, mesenchymal, or neuroendocrine tissues of the urethra, which is the fibromuscular tube that conducts urine from the urinary bladder to the external urethral orifice. In veterinary medicine, urethral tumors are uncommon but carry a grave prognosis due to their aggressive local invasion, high metastatic potential, and frequent involvement of the urinary bladder and surrounding pelvic structures. The most common histological type is transitional cell carcinoma (TCC), also known as urothelial carcinoma, which accounts for the vast majority of cases in dogs. Other reported types include squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, fibrosarcoma, hemangiosarcoma, lymphoma, and neuroendocrine tumors. Urethral neoplasia can be classified as primary (arising from the urethral epithelium or stroma) or secondary (extension from bladder tumors, prostatic tumors, or metastatic spread). Anatomically, tumors may involve the prostatic, membranous, or penile urethra in males, and the proximal or distal urethra in females. The disease is characterized by progressive urethral obstruction, dysuria, hematuria, and urinary incontinence, and it often presents at an advanced stage due to nonspecific early signs. Systemic effects include paraneoplastic syndromes such as hypercalcemia, anemia, and cachexia. Early diagnosis and multimodal therapy are essential, but long-term survival remains poor, with median survival times ranging from 6 to 12 months depending on treatment modality.

The exact etiology of urethral neoplasia is not fully understood, but several risk factors and potential causative agents have been identified. In dogs, chronic exposure to environmental carcinogens, particularly certain herbicides and insecticides, has been associated with the development of transitional cell carcinoma (TCC) of the lower urinary tract. Specifically, exposure to 4-aminobiphenyl, a component of some pesticides, and cyclophosphamide, an alkylating chemotherapeutic agent, has been implicated. In cats, urethral tumors are rare, but when they occur, they are often malignant and may be associated with feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infections, though a direct causal link is not established. Genetic predisposition plays a significant role, particularly in Scottish Terriers, Shetland Sheepdogs, Beagles, and West Highland White Terriers, which have a higher incidence of TCC. A specific genetic mutation in the BRAF gene (V595E) has been identified in a subset of canine TCCs, suggesting a molecular pathway for tumorigenesis. Chronic inflammation of the urethra, such as that caused by recurrent urinary tract infections, urolithiasis, or indwelling urinary catheters, may predispose to neoplastic transformation, although the evidence is not definitive. Hormonal factors may also contribute, as intact male dogs have a higher risk of prostatic urethral tumors, and neutered females have an increased risk of TCC. Viral etiologies, such as papillomavirus, have been suggested in some cases but are not confirmed. Overall, the etiology is likely multifactorial, involving an interaction between genetic susceptibility, environmental carcinogens, and chronic urothelial injury.

Urethral neoplasia is an uncommon condition in companion animals, with a higher prevalence in dogs than in cats. In dogs, transitional cell carcinoma (TCC) is the most common tumor of the lower urinary tract, accounting for approximately 1-2% of all canine neoplasms. The median age at diagnosis is 9-11 years, with a slight female predominance for TCC, although urethral tumors in males are often associated with prostatic involvement. Certain breeds are overrepresented, including Scottish Terriers, Shetland Sheepdogs, Beagles, West Highland White Terriers, and Airedale Terriers. In cats, urethral neoplasia is exceedingly rare, with a slight male predominance, and the median age is around 10-12 years. No specific breed predisposition has been consistently identified in cats. Geographic variation may exist due to environmental exposures, but comprehensive epidemiological data are lacking. The incidence of urethral tumors appears to be increasing, possibly due to improved diagnostic techniques and increased awareness. Metastatic disease is present in 10-20% of dogs at the time of diagnosis, with common sites including regional lymph nodes (iliac, hypogastric), lungs, liver, and bone. The aggressive nature of the disease and the advanced stage at presentation contribute to the poor prognosis.

The pathophysiology of urethral neoplasia involves the malignant transformation of urothelial or stromal cells, leading to uncontrolled proliferation, local invasion, and metastasis. In transitional cell carcinoma (TCC), the most common type, the tumor arises from the transitional epithelium lining the urethra. Genetic mutations, such as the BRAF V595E mutation in dogs, activate the MAPK signaling pathway, promoting cell proliferation and survival. Chronic inflammation and exposure to carcinogens cause DNA damage, leading to mutations in tumor suppressor genes (e.g., p53) and oncogenes. The tumor grows as a sessile, infiltrative mass, often involving the urethral wall and extending into the surrounding soft tissues, including the prostate in males and the vaginal vestibule in females. Local invasion can cause urethral obstruction, leading to urinary retention, hydronephrosis, and post-renal azotemia. The tumor may also invade blood vessels and lymphatics, leading to metastasis to regional lymph nodes (iliac, hypogastric) and distant sites, particularly the lungs. Paraneoplastic syndromes, such as hypercalcemia, may occur due to the secretion of parathyroid hormone-related protein (PTHrP) by tumor cells. The tumor microenvironment, including inflammatory cells and growth factors, supports tumor progression and angiogenesis. As the disease advances, the patient may develop cachexia, anemia, and immunosuppression, further compromising overall health.

Several intrinsic and extrinsic factors predispose animals to urethral neoplasia. Intrinsic factors include breed and genetic susceptibility, as certain breeds (e.g., Scottish Terriers) have a significantly higher risk of developing TCC. Age is a predisposing factor, with older animals (median age 9-11 years) being more commonly affected. Sex also plays a role; in dogs, females are more likely to develop TCC, while males may have a higher risk of prostatic urethral tumors. Hormonal status may influence risk, as neutered females have an increased risk of TCC, possibly due to altered urinary steroid hormone levels. Extrinsic factors include environmental exposure to carcinogens, such as certain herbicides, insecticides, and industrial chemicals. A history of chronic urinary tract infections, urolithiasis, or long-term use of indwelling urinary catheters may cause chronic urothelial irritation, potentially predisposing to neoplastic transformation. Obesity and a high body condition score have been associated with an increased risk of TCC in some studies. Additionally, previous chemotherapy with cyclophosphamide, an alkylating agent, is a known risk factor for the development of urinary bladder tumors, including TCC. In cats, viral infections (FeLV, FIV) may contribute to immunosuppression and tumor development, although the direct link is not well established.

Clinical signs of urethral neoplasia are often insidious and may be mistaken for more common lower urinary tract diseases, such as urinary tract infections or urolithiasis. The most common presenting signs include hematuria (often macroscopic), dysuria, stranguria, pollakiuria, and urinary incontinence. As the tumor grows and causes partial or complete urethral obstruction, signs of urinary obstruction may develop, including tenesmus, abdominal distension, and anuria. In male dogs, a palpable mass may be detected in the perineal or penile region, and the penis may be swollen or painful. In females, a mass may be palpable on vaginal examination. Systemic signs, such as lethargy, anorexia, weight loss, and fever, may occur in advanced disease or with metastasis. Paraneoplastic hypercalcemia can cause polyuria, polydipsia, and gastrointestinal signs. In cats, signs are similar but may be more subtle, and urethral obstruction is a common emergency presentation. Physical examination may reveal a thickened, irregular urethra on rectal palpation, an enlarged prostate in males, or a palpable abdominal mass if the bladder is distended or if there is concurrent bladder neoplasia. In advanced cases, signs of uremia, such as vomiting, dehydration, and oral ulceration, may be present due to post-renal azotemia.

The differential diagnoses for urethral neoplasia include a wide range of conditions affecting the lower urinary tract. Key differentials include: 1. **Urinary tract infection (UTI)**: Bacterial cystitis or urethritis can cause hematuria, dysuria, and pollakiuria. Urinalysis and culture are essential to differentiate; however, UTIs can coexist with neoplasia, so imaging is necessary. 2. **Urolithiasis**: Urethral calculi can cause obstruction and hematuria. Radiography or ultrasonography can identify radiopaque or radiolucent stones. 3. **Urethral stricture**: Fibrous narrowing of the urethra due to trauma, surgery, or chronic inflammation can cause obstructive signs. Contrast urethrography or urethroscopy can differentiate. 4. **Benign urethral polyps**: These are rare but can cause similar signs. Biopsy is required for definitive diagnosis. 5. **Prostatic disease in males**: Prostatic hyperplasia, prostatitis, or prostatic adenocarcinoma can cause urethral compression and similar clinical signs. Digital rectal examination, ultrasonography, and biopsy are helpful. 6. **Bladder neoplasia**: Transitional cell carcinoma of the bladder can extend into the urethra, and primary bladder tumors may present with similar signs. Cystoscopy and imaging can identify the primary site. 7. **Granulomatous urethritis**: Chronic inflammation can lead to granuloma formation, mimicking neoplasia. Biopsy is necessary. 8. **Trauma**: Urethral trauma from pelvic fractures or catheterization can cause hematuria and obstruction. History and imaging are key. 9. **Feline lower urinary tract disease (FLUTD)**: In cats, idiopathic cystitis, urolithiasis, and urethral plugs are common causes of lower urinary tract signs. These must be ruled out. 10. **Neurological disorders**: Conditions causing urinary retention, such as spinal cord disease or dysautonomia, can mimic obstruction. Neurological examination and imaging are needed.

The diagnostic approach to suspected urethral neoplasia should be systematic and stepwise. The algorithm begins with a thorough history and physical examination, including digital rectal examination in males and vaginal examination in females. If urethral neoplasia is suspected, the following steps are recommended: 1. **Initial laboratory evaluation**: Complete blood count (CBC), serum biochemistry profile, and urinalysis with urine culture and sensitivity. These tests help rule out infection, assess renal function, and identify paraneoplastic syndromes. 2. **Diagnostic imaging**: Abdominal radiography may reveal a soft tissue mass in the pelvic canal or caudal abdomen, but it is often unremarkable. Abdominal ultrasonography is more sensitive and can identify urethral thickening, bladder masses, and lymphadenopathy. Contrast urethrography (retrograde or antegrade) can delineate the extent of the urethral mass and identify filling defects. Advanced imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), is recommended for surgical planning and staging, as it provides detailed information about local invasion and metastasis. 3. **Urethroscopy**: Direct visualization of the urethral mucosa allows for identification of the mass and collection of biopsy samples. This is a minimally invasive technique that can be performed with a rigid or flexible endoscope. 4. **Biopsy and histopathology**: Definitive diagnosis requires histopathological examination of tissue samples. Biopsy can be obtained via urethroscopy, traumatic catheterization, or surgical biopsy. Fine-needle aspiration (FNA) may be attempted but often yields insufficient cells for diagnosis. 5. **Staging**: Once a diagnosis of neoplasia is confirmed, staging is essential to determine the extent of disease. This includes thoracic radiography (three views) to detect pulmonary metastasis, abdominal ultrasonography or CT to evaluate regional lymph nodes and other organs, and possibly bone scintigraphy if bone metastasis is suspected. 6. **Molecular testing**: In dogs, testing for the BRAF V595E mutation in urine or tissue samples can support the diagnosis of TCC and may be useful for monitoring response to therapy.

Laboratory findings in urethral neoplasia are often nonspecific but can provide supportive evidence and help rule out other conditions. On complete blood count (CBC), anemia may be present due to chronic disease, blood loss, or paraneoplastic syndromes. Leukocytosis may occur if there is concurrent infection or inflammation. Serum biochemistry may reveal azotemia (elevated blood urea nitrogen and creatinine) if urethral obstruction has caused post-renal kidney injury. Hypercalcemia may be present in cases of paraneoplastic hypercalcemia, particularly with TCC. Hypoalbuminemia may occur due to chronic inflammation or protein-losing nephropathy. Urinalysis is a critical component; common findings include hematuria, pyuria, and proteinuria. The urine sediment may contain atypical transitional epithelial cells, which can be suggestive of neoplasia but are not diagnostic. Urine culture should be performed to rule out bacterial infection, which is a common concurrent finding. Urinary biomarkers, such as the BRAF V595E mutation test in dogs, can be performed on urine samples and have high sensitivity and specificity for TCC. Other biomarkers, such as bladder tumor antigen (BTA) tests, have been evaluated but are less specific. In cases of suspected metastasis, serum alkaline phosphatase may be elevated if there is liver involvement, and calcium and phosphorus levels should be monitored.

Imaging plays a crucial role in the diagnosis and staging of urethral neoplasia. Abdominal radiography may show a soft tissue mass in the pelvic canal or caudal abdomen, but it is often unremarkable in early disease. In cases of urethral obstruction, the urinary bladder may be distended. Contrast urethrography, either retrograde or antegrade, is a valuable technique for evaluating the urethral lumen. It can reveal filling defects, irregular mucosal margins, and strictures. In male dogs, a retrograde urethrogram is performed by injecting contrast medium into the distal urethra; in females, a catheter is placed in the vestibule. Ultrasonography is highly useful for evaluating the urethra, especially the proximal portion. It can identify thickening of the urethral wall, a mass lesion, and extension into the bladder or prostate. Doppler ultrasonography can assess vascularity. Computed tomography (CT) is the preferred imaging modality for staging and surgical planning. It provides excellent anatomical detail, allowing for assessment of local invasion, lymph node enlargement, and pulmonary metastasis. CT urethrography, which combines CT with contrast administration, is particularly useful. Magnetic resonance imaging (MRI) may be used for soft tissue characterization, but it is less commonly available and more expensive. Urethroscopy allows direct visualization of the mass and can be used to obtain biopsies. In cases of suspected metastasis, thoracic radiography (three views) is essential to detect pulmonary nodules.

Cytological and histopathological evaluation is essential for definitive diagnosis of urethral neoplasia. Fine-needle aspiration (FNA) of a urethral mass may be performed, but it is often challenging due to the location and the desmoplastic nature of the tumor. When cytology is obtained, it may show clusters of transitional epithelial cells with criteria of malignancy, such as anisocytosis, anisokaryosis, prominent nucleoli, and high nuclear-to-cytoplasmic ratio. However, cytology alone is often insufficient to differentiate neoplasia from severe inflammation or hyperplasia. Histopathology is the gold standard. Biopsy samples can be obtained via urethroscopy, traumatic catheterization, or surgical biopsy. In dogs, a traumatic catheterization technique using a urinary catheter to scrape the urethral mucosa can yield samples for histology. Histologically, transitional cell carcinoma (TCC) is characterized by infiltrative cords and nests of pleomorphic urothelial cells with varying degrees of squamous or glandular differentiation. The tumor often invades the lamina propria and muscularis. Other tumor types, such as squamous cell carcinoma, show keratin pearls and intercellular bridges. Leiomyosarcoma is characterized by interlacing bundles of spindle cells with smooth muscle differentiation. Immunohistochemistry (IHC) can be used to confirm the histogenesis; for example, TCC is typically positive for cytokeratin and uroplakin III, while leiomyosarcoma is positive for smooth muscle actin. Special stains, such as periodic acid-Schiff (PAS), may be used to identify mucin production in adenocarcinomas. The presence of lymphatic or vascular invasion is a poor prognostic indicator.

Treatment of urethral neoplasia is challenging and often requires a multimodal approach. The primary goals are to relieve urethral obstruction, control local disease, and manage metastasis. Treatment options include surgery, radiation therapy, chemotherapy, and palliative care. Surgical resection is the treatment of choice for localized tumors, but it is often not feasible due to the location and extent of the tumor. In male dogs, tumors involving the prostatic urethra may require cystoprostatectomy, which is associated with significant morbidity and a high rate of complications. In female dogs, urethrectomy with urinary diversion (e.g., cystostomy tube or ureterocolonic anastomosis) may be considered, but these procedures are associated with a poor quality of life. Therefore, medical management is often preferred. Chemotherapy is the mainstay of treatment for TCC. The most commonly used protocol is a combination of mitoxantrone (5 mg/m² IV every 3 weeks) and a nonsteroidal anti-inflammatory drug (NSAID), such as piroxicam (0.3 mg/kg PO every 24 hours). This protocol has been shown to improve survival and quality of life. Other chemotherapeutic agents, such as carboplatin (300 mg/m² IV every 3 weeks), vinblastine (2 mg/m² IV every 2 weeks), and chlorambucil (4-6 mg/m² PO every 24 hours), have been used with variable success. Radiation therapy, particularly stereotactic radiation, can be effective for local control and palliation of obstructive signs. It is often used in combination with chemotherapy. In cases of urethral obstruction, emergency management may include placement of a cystostomy tube or urethral stenting to relieve the obstruction. Urethral stenting using a self-expanding metallic stent can provide immediate relief of obstruction and is a minimally invasive option. Supportive care includes pain management, antiemetics, and nutritional support. In cases of paraneoplastic hypercalcemia, treatment with saline diuresis, furosemide, and bisphosphonates may be necessary.

The prognosis for urethral neoplasia is generally poor, with a median survival time of 6 to 12 months in dogs with TCC treated with chemotherapy and NSAIDs. Factors associated with a worse prognosis include the presence of metastasis at diagnosis, high tumor grade, invasion into surrounding tissues, and the development of urethral obstruction. Dogs that achieve a complete or partial response to chemotherapy have a longer survival time. The use of piroxicam alone has been shown to produce a partial response in about 20% of dogs, with a median survival of about 6 months. Combination therapy with mitoxantrone and piroxicam has a median survival of about 9-12 months. In cats, the prognosis is even worse, with most cats surviving less than 6 months. The presence of paraneoplastic hypercalcemia is a negative prognostic indicator. Urethral obstruction is a common complication and can lead to life-threatening azotemia if not managed promptly. Despite aggressive treatment, local recurrence and metastasis are common. Long-term survival (>2 years) is rare but has been reported in a small percentage of dogs with low-grade tumors that undergo complete surgical resection. Palliative care can improve quality of life but does not significantly alter survival.

Follow-up care for patients with urethral neoplasia is essential to monitor response to therapy, detect complications, and manage side effects. Patients should be re-evaluated at regular intervals, typically every 3-4 weeks during chemotherapy. At each visit, a physical examination, including digital rectal examination, should be performed. Complete blood count and serum biochemistry should be monitored to assess for myelosuppression, renal function, and electrolyte imbalances. Urinalysis and urine culture should be performed if there are signs of urinary tract infection. Imaging, such as abdominal ultrasonography or CT, should be repeated every 2-3 months to assess tumor size and detect metastasis. Thoracic radiography should be performed every 3-4 months to screen for pulmonary metastasis. The BRAF V595E mutation test can be used to monitor response to therapy in dogs, as levels may decrease with successful treatment. If the patient has a urethral stent, regular assessment of stent patency is necessary. Owners should be educated to monitor for signs of obstruction, such as straining to urinate, and to seek immediate veterinary care if these occur. Dose adjustments of chemotherapeutic agents may be necessary based on hematologic and gastrointestinal toxicity. Long-term management includes continued NSAID therapy, which requires monitoring for gastrointestinal and renal side effects. Quality of life should be assessed regularly, and palliative care should be adjusted as needed.

Clinical Pearls: - Always perform a digital rectal examination in male dogs with lower urinary tract signs, as urethral masses may be palpable. - In female dogs, a vaginal examination can help identify a urethral mass. - Urine culture is essential, as concurrent urinary tract infections are common and can complicate the clinical picture. - The BRAF V595E mutation test is a valuable, non-invasive diagnostic tool for TCC in dogs, with high sensitivity and specificity. - Piroxicam is a cornerstone of therapy for TCC; it has both anti-inflammatory and potential antitumor effects. - Urethral stenting can provide rapid relief of obstruction and improve quality of life in patients with advanced disease. - Consider paraneoplastic hypercalcemia in any dog with TCC and polyuria/polydipsia. Clinical Pitfalls: - Do not assume that hematuria and dysuria are due to a simple urinary tract infection; always consider neoplasia in older animals, especially in high-risk breeds. - Avoid performing a cystotomy or urethrotomy without prior imaging, as this may disseminate tumor cells. - Do not use corticosteroids in place of NSAIDs for TCC, as they may be less effective and have more side effects. - Be cautious with the use of NSAIDs in patients with renal impairment or gastrointestinal disease; monitor for toxicity. - Do not delay definitive diagnosis; early intervention can improve outcomes. - Avoid using a transurethral catheter to relieve obstruction if a tumor is suspected, as this may cause trauma and bleeding. - Do not forget to stage the disease; metastasis is present in a significant number of cases at diagnosis.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used for urethral neoplasia, particularly transitional cell carcinoma (TCC): 1. **Piroxicam**: 0.3 mg/kg PO every 24 hours (dogs). Administer with food to reduce gastrointestinal upset. Contraindicated in patients with gastrointestinal ulcers, renal disease, or bleeding disorders. Monitor for vomiting, diarrhea, and elevated renal parameters. 2. **Mitoxantrone**: 5 mg/m² IV every 3 weeks (dogs). Administer as a slow IV infusion over 5-10 minutes. Monitor for myelosuppression (neutropenia) and cardiotoxicity. Adjust dose in patients with hepatic impairment. 3. **Carboplatin**: 300 mg/m² IV every 3 weeks (dogs). Administer as a slow IV infusion over 15-30 minutes. Monitor for myelosuppression and nephrotoxicity. Dose adjustment is necessary in patients with renal insufficiency. 4. **Vinblastine**: 2 mg/m² IV every 2 weeks (dogs). Administer as a slow IV push. Monitor for myelosuppression and neurotoxicity. 5. **Chlorambucil**: 4-6 mg/m² PO every 24 hours (dogs). Administer on an empty stomach. Monitor for myelosuppression and gastrointestinal toxicity. 6. **Furosemide**: 1-2 mg/kg IV or PO every 8-12 hours, used for management of hypercalcemia. Monitor for dehydration and electrolyte imbalances. 7. **Bisphosphonates (e.g., pamidronate)**: 1-2 mg/kg IV diluted in saline, administered over 2-4 hours, for hypercalcemia. Monitor for renal toxicity. 8. **Supportive care**: Maropitant (1 mg/kg IV or PO every 24 hours) for nausea, and ondansetron (0.1-0.2 mg/kg IV every 8-12 hours) for vomiting. Pain management may include tramadol (2-5 mg/kg PO every 8-12 hours) or gabapentin (5-10 mg/kg PO every 8-12 hours). All chemotherapeutic agents should be handled with caution, and appropriate safety protocols should be followed. Dosages should be adjusted based on body surface area, and hematologic monitoring is essential.

The literature on urethral neoplasia in veterinary medicine is limited but provides valuable insights. A landmark study by Knapp et al. (1994) demonstrated that piroxicam alone produced a partial response in 20% of dogs with TCC, with a median survival of 6 months. Subsequent studies evaluated combination therapy with mitoxantrone and piroxicam, showing a median survival of approximately 9-12 months (Henry et al., 2003). A study by Mutsaers et al. (2003) reported that the addition of mitoxantrone to piroxicam improved response rates but did not significantly prolong survival compared to piroxicam alone. More recent studies have investigated the use of vinblastine and carboplatin in the treatment of TCC, with response rates ranging from 20-40%. The BRAF V595E mutation was identified by Decker et al. (2015) and has been validated as a diagnostic and monitoring tool. A study by Fulkerson et al. (2017) evaluated the use of urethral stenting for obstructive TCC, reporting successful relief of obstruction in 95% of cases, with a median survival of 3 months post-stenting. Radiation therapy, particularly stereotactic body radiation therapy (SBRT), has been evaluated in small studies, showing promising local control rates (Nolan et al., 2017). Consensus guidelines from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and treatment of lower urinary tract tumors were published in 2016, recommending a multimodal approach with surgery, chemotherapy, and radiation therapy as appropriate. Overall, the evidence supports the use of piroxicam as a foundation, with the addition of chemotherapy for more aggressive disease, and emphasizes the importance of early diagnosis and staging.